H.C. Wainwright raised the firm’s price target on Biogen (BIIB) to $194 from $187 and keeps a Buy rating on the shares post the Q2 report. The company announced that the felzartamab Phase 3 studies have advanced to registrational stage in IgA nephropathy and primary membranous nephropathy, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Cautious Hold on Biogen Amid Modest Growth Prospects and Uncertain Pipeline
- Biogen Reports Strong Q2 2025 Results, Raises Guidance
- Biogen price target lowered to $144 from $146 at Morgan Stanley
- Biogen’s Litifilimab Study: A Long-Term Hope for Lupus Treatment
- Morning Movers: Roblox skyrockets following second quarter results